8.935

1.76% -0.165

Aurinia Pharmaceuticals Inc (AUPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt AUPH? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$9.10

Offen:

$9.1

24-Stunden-Volumen:

848.59K

Relative Volume:

0.71

Marktkapitalisierung:

$1.28B

Einnahmen:

$175.51M

Nettoeinkommen (Verlust:

$-78.02M

KGV:

-16.86

EPS:

-0.53

Netto-Cashflow:

$-34.18M

1W Leistung:

+2.64%

1M Leistung:

+22.13%

6M Leistung:

+66.79%

1J Leistung:

-1.33%

1-Tages-Spanne:

$8.88

$9.17

1-Wochen-Bereich:

$8.70

$9.24

52-Wochen-Spanne:

$4.71

$9.74

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Firmenname

Aurinia Pharmaceuticals Inc

Sektor

Healthcare (1180)

Branche

Biotechnology (683)

Telefon

250-744-2487

Adresse

#140, 14315 - 118 AVENUE, EDMONTON, BC

Mitarbeiter

300

Twitter

@AuriniaPharma

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

AUPH's Discussions on Twitter

Vergleichen Sie AUPH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AUPH Aurinia Pharmaceuticals Inc	8.935	1.28B	175.51M	-78.02M	-34.18M	-0.53
VRTX Vertex Pharmaceuticals Inc	459.74	119.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	748.82	82.77B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	610.96	37.02B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.13	32.26B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.14	28.24B	3.30B	-501.07M	1.03B	-2.1146

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-11-04	Herabstufung	Oppenheimer	Outperform → Perform
2022-05-05	Fortgesetzt	Cantor Fitzgerald	Overweight
2021-12-10	Hochstufung	Oppenheimer	Perform → Outperform
2021-10-28	Herabstufung	Oppenheimer	Outperform → Perform
2021-01-25	Bestätigt	H.C. Wainwright	Buy
2020-11-03	Bestätigt	H.C. Wainwright	Buy
2020-06-17	Eingeleitet	BTIG Research	Buy
2020-05-05	Eingeleitet	Cowen	Outperform
2020-01-10	Eingeleitet	Jefferies	Buy
2019-12-16	Bestätigt	H.C. Wainwright	Buy
2018-03-16	Bestätigt	Cantor Fitzgerald	Overweight
2018-02-08	Eingeleitet	RBC Capital Mkts	Outperform
2017-10-30	Bestätigt	H.C. Wainwright	Buy
2017-05-18	Bestätigt	H.C. Wainwright	Buy
2017-04-11	Eingeleitet	Cantor Fitzgerald	Overweight
2017-03-22	Bestätigt	FBR & Co.	Outperform
2016-12-30	Bestätigt	H.C. Wainwright	Buy
2016-08-17	Bestätigt	H.C. Wainwright	Buy
2016-06-30	Eingeleitet	H.C. Wainwright	Buy
2015-05-08	Eingeleitet	MLV & Co	Buy

Alle ansehen

Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten

Dec 01, 2024

PDT Partners LLC Buys 130,204 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Dec 01, 2024

Nov 30, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Algert Global LLC - MarketBeat

Nov 30, 2024

Nov 25, 2024

Connor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Nov 25, 2024

Nov 22, 2024

Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace

Nov 22, 2024

Nov 20, 2024

Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - MSN

Nov 20, 2024

Nov 18, 2024

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - sharewise

Nov 18, 2024

Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines - TipRanks

Nov 18, 2024

Nov 17, 2024

(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 17, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat

Nov 17, 2024

Nov 15, 2024

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - sharewise

Nov 15, 2024

Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024

ARMISTICE CAPITAL, LLC's Strategic Reduction in Aurinia Pharmace - GuruFocus.com

Nov 15, 2024

Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock - Investing.com India

Nov 14, 2024

Nov 13, 2024

Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock By Investing.com - Investing.com Nigeria

Nov 13, 2024

Nov 12, 2024

Aurinia Pharmaceuticals director sells shares valued at $38,415 - Investing.com India

Nov 12, 2024

Aurinia Pharmaceuticals director sells shares valued at $38,415 By Investing.com - Investing.com Canada

Nov 12, 2024

Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com - Defense World

Nov 12, 2024

Aurinia Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 12, 2024

Nov 11, 2024

Aurinia stock jumps 14% on Q3 earnings, restructuring announcement - MSN

Nov 11, 2024

Aurinia offers slimmer profile after investor pressure - The Pharma Letter

Nov 11, 2024

Leerink Partnrs Issues Optimistic Estimate for AUPH Earnings - MarketBeat

Nov 11, 2024

Nov 09, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon (NASDAQ:AUPH) - Seeking Alpha

Nov 08, 2024

Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets - Pharmaceutical Technology

Nov 08, 2024

Nov 07, 2024

Earnings call: Aurinia Pharmaceuticals announced a 24% increase in total net revenue - Investing.com

Nov 07, 2024